A critical advance in cancer research is occurring with the use of mini-antibodies to re-engage dysfunctional p53. This vital malignant protector protein is frequently disabled in several types of cancer, resulting https://worldsocialindex.com/story7058090/mini-antibodies-reactivate-p53-the-new-hope-for-malignant-management